Try our maximum weight loss GLP starting at $120. Money-back guarantee. Click here.

Deer Supply & Research

Compare · weight-loss medicine

One family of medicine. Three generations.

Semaglutide, Tirzepatide, and Retatrutide all act on the GLP-1 system, but each newer molecule adds another target, and trials tend to report more average weight loss as they do. Here is how they line up on the published data.

Average weight loss in trials

More targets, more weight lost on average.

Average total body-weight reduction at the highest studied dose in each molecule's landmark trial. Different studies, populations, and timeframes, shown for general comparison only.

Semaglutide

GLP-1 · STEP 1, 2.4 mg, 68 weeks

~15%

Tirzepatide

GLP-1 + GIP · SURMOUNT-1, 15 mg, 72 weeks

~21%

Retatrutide

GLP-1 + GIP + glucagon · TRIUMPH-1 Phase 3, 12 mg, 80 weeks

~28%
Sources: STEP 1 (NEJM 2021) · SURMOUNT-1 (NEJM 2022) · TRIUMPH-1 Phase 3 (2025). Average total body-weight reduction at the highest studied dose in each landmark trial. Trial averages from separate studies, not a prediction of individual results.

Your turn

Calculate what you could lose

Enter your current weight and see what each medication's trial average could add up to. An "up to" estimate, never a promise.

Example projection

Retatrutide · trial average

up to 62 lb

from a 220 lb start

Trial average applied to an example, not a prediction

Side by side

The full picture.

AttributeSemaglutideTirzepatideRetatrutide
GenerationFirstSecondThird
Receptor targetsGLP-1GLP-1 + GIPGLP-1 + GIP + glucagon
Avg. weight loss in trial~15%in STEP 1~21%in SURMOUNT-1~28%in TRIUMPH-1
Landmark trialSTEP 1 (2.4 mg)SURMOUNT-1 (15 mg)TRIUMPH-1 (12 mg)
Trial length68 weeks72 weeks80 weeks
DosingWeekly injectionWeekly injectionWeekly injection
Also known asOzempic / WegovyMounjaro / ZepboundExclusively at Deer
At Deer fromFrom $90From $230From $150
ShopShop SemaglutideShop TirzepatideShop Retatrutide

Trial figures are averages from separate published studies, not a prediction of individual results.

How they work

Each target adds another lever.

GLP-1

The appetite signal

The GLP-1 pathway is linked to fullness, slower stomach emptying, and blood-sugar control. Every molecule here acts on it.

GIP

The second hormone

Tirzepatide adds GIP, another gut hormone involved in how the body handles food energy and insulin response.

GCG

The energy lever

Retatrutide adds glucagon activity, which is associated with energy expenditure, on top of the GLP-1 and GIP targets.

Price · vs the alternatives

What the same medicine costs elsewhere.

Listed Canadian pricing for comparable packages, framed per month at the trial dose. Pharmacy prices are approximate retail.

Semaglutide vs Ozempic

Per month at 2 mg weekly
OptionPackageListed pricePer month
Deer Semaglutide10 mg pen$140~$112
Apo-Semaglutide8 mg (2 x 4 mg)$176Approx. retail~$176
Ozempic8 mg (2 mg weekly)$450Approx. retail~$450

Deer Semaglutide is $140 for a 10 mg pen. Apo-Semaglutide lists at about $176 for 8 mg and brand-name Ozempic at about $450 for 8 mg (Costco, Ontario).

Tirzepatide vs Mounjaro

Per month at 15 mg weekly
OptionPackageListed pricePer month
Deer Tirzepatide2 x 60 mg (8 weeks)$580~$290
Mounjaro60 mg (4 weeks)$450Approx. retail~$450

Deer Tirzepatide is $580 for two months at 15 mg weekly (two 60 mg pens), versus about $900 over the same two months at roughly $450 per month for Mounjaro.

Pharmacy prices are approximate Canadian retail and change over time. Final totals depend on product, shipping region, and order confirmation.

Next step

Find the option that fits your plan.

Answer four questions and get matched to one of the three, or browse every weight-loss pen and build your cart.

The figures above are average results from separate published clinical trials, each with different participants, doses, and durations, and are shown only for general comparison. They are not a prediction of your results, and Deer does not claim any product will produce them. Individual results vary. This page is general education, not medical advice, and products are subject to eligibility review.